Combination Therapy with Doxorubicin-Loaded Reduced Albumin Nanoparticles and Focused Ultrasound in Mouse Breast Cancer Xenografts
| Autor: | Seung Soo Lee, Hyungwon Moon, Hak Jong Lee, Woo Young Yoo, Yoon Seok Kim, Ae-Sin Cho, Hyun Ryoung Kim, So Yeon Park, Dae-Hyun Kim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
Combination therapy media_common.quotation_subject lcsh:Medicine lcsh:RS1-441 Pharmaceutical Science Nanoparticle Pharmacology doxorubicin Article lcsh:Pharmacy and materia medica 03 medical and health sciences breast cancer 0302 clinical medicine Breast cancer Drug Discovery medicine Doxorubicin albumin nanoparticles 030304 developmental biology media_common 0303 health sciences Chemistry lcsh:R Albumin medicine.disease 030220 oncology & carcinogenesis drug delivery Toxicity Drug delivery focused ultrasound Molecular Medicine medicine.drug |
| Zdroj: | Pharmaceuticals Volume 13 Issue 9 Pharmaceuticals, Vol 13, Iss 235, p 235 (2020) |
| ISSN: | 1424-8247 |
| DOI: | 10.3390/ph13090235 |
| Popis: | Because chemotherapeutic drugs are often associated with serious side effects, the central topic in modern drug delivery is maximizing the localization of drugs at the target while minimizing non-specific drug interactions at unwanted regions. To address this issue, biocompatible nanoparticles have been developed to enhance the drug half-life while minimizing the associated toxicity. Nevertheless, relying solely on the enhanced half-life and enhanced permeability and retention (EPR) effects has been ineffective, and designing stimulus-sensitive nanoparticles to introduce the precise control of drug release has been desired. In this paper, we introduce a pH-sensitive, reduced albumin nanoparticle in combination with focused ultrasound treatment. Not only did these nanoparticles have superior therapeutic efficacy and toxicity profiles when compared to the free drugs in xenograft mouse models, but we were also able to show that the albumin nanoparticles reported in this paper were more suitable than other types of non-reduced albumin nanoparticles as vehicles for drug delivery. As such, we believe that the albumin nanoparticles presented in this paper with desirable characteristics including the induction of strong anti-tumor response, precise control, and superior safety profiles hold strong potential for preclinical and clinical anticancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |